Woodline Partners’s Structure Therapeutics GPCR Stock Holding History

Woodline Partners’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.2M	Buy	190,808 +66,906	+54%	+$4.58M	0.03%	531
2025 Q4	$8.62M	Buy	123,902 +58,462	+89%	+$2.39M	0.03%	496
2025 Q3	$1.83M	Sell	65,440 -111,013	-63%	-$2.21M	0.01%	737
2025 Q2	$3.66M	Buy	176,453 +1,029	+0.6%	+$22.6K	0.02%	617
2025 Q1	$3.04M	Sell	175,424 -158,477	-47%	-$3.88M	0.02%	605
2024 Q4	$9.06M	Buy	333,901 +2,328	+0.7%	+$82.6K	0.06%	368
2024 Q3	$14.6M	Sell	331,573 -5,828	-2%	-$225K	0.12%	233
2024 Q2	$13.2M	Buy	337,401 +157,509	+88%	+$6.47M	0.13%	218
2024 Q1	$7.71M	Buy	179,892 +673	+0.4%	+$28.4K	0.07%	306
2023 Q4	$7.3M	Buy	179,219 +9,219	+5%	+$528K	0.08%	265
2023 Q3	$8.57M	Hold	170,000	–	–	0.1%	243
2023 Q2	$7.07M	Hold	170,000	–	–	0.08%	253
2023 Q1	$4.04M	Buy	+170,000	New	+$3.99M	0.06%	321

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Woodline Partners's GPCR Position: Q1 2026 in Review

Woodline Partners increased its Structure Therapeutics (GPCR) stake by 54% in Q1 2026, buying an estimated $4.58M and bringing the position to 190,808 shares worth $9.2M. The position accounts for 0.03% of the portfolio, ranked #531.

Woodline Partners first reported a position in GPCR in Q1 2023 and has held it in 13 quarters since. The position peaked at $14.6M in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Woodline Partners held 190,808 shares of Structure Therapeutics worth $9.2M as of Q1 2026.
Woodline Partners bought 66,906 Structure Therapeutics shares in Q1 2026, an estimated $4.58M.
Structure Therapeutics made up 0.03% of Woodline Partners's portfolio in Q1 2026, its #531 holding.
Woodline Partners first reported a position in Structure Therapeutics in Q1 2023 and has held it in 13 quarters since.
Woodline Partners's Structure Therapeutics position peaked at $14.6M in Q3 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.